OXB

Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, OXB, Growth, Transaction, CDMO, European, COVID-19, Oxford Biomedica, BST, AAV, Lentivirus, VWAP

Additionally, the Company announces that it will report its Preliminary Results for the twelve months ended 31 December 2023 on Monday 29 April 2024.

Key Points: 
  • Additionally, the Company announces that it will report its Preliminary Results for the twelve months ended 31 December 2023 on Monday 29 April 2024.
  • In line with guidance provided at the Interim Results, revenues for the year ended 31 December 2023 are expected to be approximately £90 million.
  • Operating EBITDA loss for the second half of 2023 is on track to be approximately £10 million better than the first half, as previously guided.
  • A briefing for investors and analysts will take place at 13:00 BST / 08:00 ET at One Moorgate Place, London, EC2R 6EA.

Oxford Biomedica completes acquisition of ABL Europe

Retrieved on: 
Monday, January 29, 2024
Vivisection, London Stock Exchange Group, European, Official List, London Stock Exchange, MVA, ABL, Lentivirus, Acquisition, CDMO, OXB

Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK

Key Points: 
  • Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK
    Expands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues
    Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023 , it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA ("Institut Mérieux").
  • The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica's position as a world-leading cell and gene therapy CDMO.
  • In addition, the acquisition increases Oxford Biomedica's capacity in process and analytical development and early-stage manufacturing across Adenovirus, Lentiviral vectors, AAVs and with this acquisition, MVA and Vaccinia.
  • This transaction opens up exciting growth opportunities for ABL Europe, that will significantly expand their offering to biopharma and biotech companies, and ultimately help more patients.”

Business Update

Retrieved on: 
Thursday, December 7, 2023
Workforce, Conference, IND, Sale, Oxford Biomedica, Acquisition, 5L, European, CDMO, 7L, Investigational New Drug, Lentivirus, COVID-19, AAV, Annual, IMPD, Growth, OXB, Vaccine

Oxford Biomedica has made significant progress in its streamlining of operations to become a pure-play quality and innovation-led global cell and gene therapy CDMO.

Key Points: 
  • Oxford Biomedica has made significant progress in its streamlining of operations to become a pure-play quality and innovation-led global cell and gene therapy CDMO.
  • This organisational restructuring is tailored to boost efficiency and client-centricity, aligning roles and operations with the specific requirements of a pure-play CDMO.
  • The Company continues to demonstrate robust business development activity, a testament to its strong position in the viral vector space.
  • The Company also remains on track to deliver broadly breakeven Operating EBITDA in 2024, bolstered by positive momentum in business development activities and new orders recently secured across lentivirus, adenoviral vectors and AAV, with both new and existing clients.

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO

Retrieved on: 
Monday, December 4, 2023
Depreciation, Sale, Virus, Acquisition, Completion, European, Transaction, CDMO, Official List, Potyvirus, VWAP, OXB, London Stock Exchange

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO

Key Points: 
  • Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
    Provides Oxford Biomedica with multi viral vector CDMO capabilities – to be made available across the Company’s six manufacturing sites in EU, US and UK
    Oxford, UK – 4 December 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into a sale and purchase agreement (the “Agreement”) with TSGH SAS, a subsidiary of Institut Mérieux SA ("Institut Mérieux"), for the acquisition of ABL Europe SAS (“ABL Europe”) (the "Transaction").
  • The acquisition of ABL Europe will consolidate Oxford Biomedica's operations into a global pure-play CDMO in the cell and gene therapy space.
  • ABL Europe currently works on more than 10 cell and gene therapy programmes spanning disease areas including more than six different vector types.
  • Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “The acquisition of ABL Europe strengthens Oxford Biomedica's operations into a global pure-play CDMO in the cell and gene therapy space.

ViroCell Expands Business Development Team to Support Next Phase of Growth

Retrieved on: 
Wednesday, October 4, 2023
Health, Genetics, Stem Cells, Pharmaceutical, Clinical Trials, Molecular oncology, Duke University, LSE, Business development, University, Oxford Biomedica, Therapy, Gene, Biotechnology, Business, TMO, Thermo Fisher Scientific, CMDO, CTLT, Organic, Doctor of Philosophy, OXB, Colon, Regenerative medicine, Harvard Medical School, CDMO, Patient, Mesa, Cell, CFO, Growth, Commercial Operating System, Ecosystem, Newcastle University, Team, NYSE, Catapult, National Technical University of Athens, Non-executive director, Pharmaceutical industry, Fine chemical, Science, Biology

Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCell from roles across CMDO businesses focused on cell and gene therapy.

Key Points: 
  • Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCell from roles across CMDO businesses focused on cell and gene therapy.
  • Joining ViroCell to accelerate business growth across Europe, Makis brings over 25 years of biopharmaceutical experience marked by contributions to the development of innovative biotechnology products and successful businesses.
  • Most recently, he was Director of Business Development at Catalent Cell and Gene Therapy (“Catalent”, NYSE: CTLT), a CDMO specialising in advanced therapeutics.
  • Before this, Makis worked at the UK’s Cell and Gene Therapy Catapult as a Business Development Manager.

Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation

Retrieved on: 
Wednesday, September 20, 2023
GMP, LSE, Official List, Poxviridae, Oxford, QC, European Union (Withdrawal) Act 2018, London Stock Exchange, AGM, Equity, Immunotherapy, OXB, Lentivirus, CDMO, EBITDA, Acquisition, VWAP, Financial Conduct Authority, Vivisection, Potyvirus, ABL, Depreciation, Growth, Virus, Companies Act 2006, Completion, MVA, Vaccine, Fine chemical, Retail, Bookkeeping, Oxford Biomedica, EU, Vaccinia, European, Adenoviridae

596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

Key Points: 
  • 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).
  • This Proposed Transaction would form part of Oxford Biomedica’s transformation to be a world-leading quality focused and innovation-led CDMO in the cell and gene therapy field.
  • As at 31 December 2022, ABL Europe had earnings before interest tax and depreciation (EBITDA) of c.€(1.7)m and gross assets of c.€23.6m.
  • Currently, the Proposed Transaction would constitute a Class 2 transaction for the purposes of the UK Financial Conduct Authority’s Listing Rules.

Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023

Retrieved on: 
Wednesday, September 20, 2023
Workforce, LSE, Oxford Biomedica, Q&A, European Union (Withdrawal) Act 2018, Unless, Pakistan Software Export Board, COVID-19, GAAP, CCO, OXB, Science, CDMO, Annual report, EBITDA, Acquisition, Patient, CFO, Growth, BST, Management, Rare-earth element, Sales, Retail, Pharmaceutical industry, Cryptocurrency, Tutoring, EU, Depreciation, Atlantic Ocean

Dr. Frank Mathias, Oxford Biomedica’s Chief Executive Officer, said:

Key Points: 
  • Dr. Frank Mathias, Oxford Biomedica’s Chief Executive Officer, said:
    “Oxford Biomedica is a market leader in the fast-growing gene and cell therapy market.
  • I value our staff tremendously and thank everyone for their hard work and contribution to Oxford Biomedica both now and into the future.
  • Cash at 30 June 2023 was 9% higher at £129.4 million compared to £118.5 million at 30 June 2022.
  • The net cash position was 16% higher at £90.1 million as of 30 June 2023 (30 June 2022: £78.7 million).

Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform

Retrieved on: 
Wednesday, September 20, 2023
LSE, Partnership, Oxford Biomedica, CD19, Anti-CD19 immunotoxin, OXB, Development, CAR, CDMO, Patient, Engineering, Lupus nephritis, Vaccine

EMERYVILLE, Calif., Sept. 20, 2023 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced a non-exclusive, multi-year license and supply agreement with Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"), a quality and innovation-led viral vector Contract and Development Manufacturing Organization (CDMO), enabling the use of LentiVector® with any Kyverna product.

Key Points: 
  • EMERYVILLE, Calif., Sept. 20, 2023 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced a non-exclusive, multi-year license and supply agreement with Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"), a quality and innovation-led viral vector Contract and Development Manufacturing Organization (CDMO), enabling the use of LentiVector® with any Kyverna product.
  • The LentiVector® platform is the first commercially approved lentiviral-based gene delivery system.
  • The platform enables the successful development of breakthrough gene and cell-based medicines.
  • "We are delighted to be working with Oxford Biomedica, a recognized leader in reliable, quality vector supply.

Oxford Biomedica to host webinar showcasing the TetraVecta™ system

Retrieved on: 
Thursday, September 7, 2023
Vector, LSE, CDMO, Oxford Biomedica, Platform, Q&A, OXB, BST, Vaccine

Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVectaTM system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023.

Key Points: 
  • Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVectaTM system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023.
  • The webinar titled “4th Generation Lentiviral Vectors: An Improved Gene Delivery System” will feature presentations by Dr Nick Clarkson, Vice President, Head of Platform Research at Oxford Biomedica and Dr Dan Farley, Senior Director of the Vector Engineering Group at Oxford Biomedica, who will discuss how the TetraVecta™ system can significantly enhance the development and manufacturing of safer and more effective lentiviral vector-based therapies through improved quality, potency and packaging capacity.
  • The webinar will be held at 16:00 BST / 11:00 EST on Monday 2 October 2023, followed by a live Q&A session.
  • Oxford Biomedica’s TetraVectaTM system launched in May 2023 following years of development and on the basis of detailed understanding of specific industry challenges.

BenevolentAI: Appointment of Catherine Isted, ACMA, as Chief Financial Officer

Retrieved on: 
Monday, September 11, 2023
Software, Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Professional Services, Technology, MSD, Morgan Stanley, Katherine, LSE, AIM, Oxford Biomedica, Nomura, ABN, ABN AMRO, Research, ReNeuron, OXB, BAI, ACMA, CDMO, Merck & Co., Partner, Chemistry, Euronext Amsterdam, CFO, Growth, Merck Sharp & Dohme Federal Credit Union, Corporate development, Management

BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in the development of advanced AI that accelerates biopharma discovery, announces the appointment of Catherine Isted, ACMA, who will be joining the Company as Chief Financial Officer (CFO) with immediate effect.

Key Points: 
  • BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in the development of advanced AI that accelerates biopharma discovery, announces the appointment of Catherine Isted, ACMA, who will be joining the Company as Chief Financial Officer (CFO) with immediate effect.
  • Catherine is an experienced strategic finance professional and chartered accountant with over 25 years within the life sciences industry.
  • She was most recently Chief Executive Officer of ReNeuron (AIM: RENE), a UK-based leader in stem cell-derived exosome technologies, having previously been CFO.
  • Joanna Shields, Chief Executive Officer of BenevolentAI, commented: “We are delighted to welcome Catherine to the BenevolentAI Executive Leadership Team.